NASDAQ:LMNX - Luminex Stock Price, News & Analysis

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex announced a quarterly dividend on Wednesday, July 31st. Stockholders of record on Thursday, September 26th will be given a dividend of $0.09 per share on Thursday, October 17th. This represents a $0.36 annualized dividend and a dividend yield of 1.61%. The ex-dividend date is Wednesday, September 25th. This is a boost from Luminex's previous quarterly dividend of $0.06. View Luminex's Dividend History.

Luminex Co. (NASDAQ:LMNX) issued its quarterly earnings results on Wednesday, July, 31st. The medical instruments supplier reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.09. The medical instruments supplier had revenue of $83.06 million for the quarter, compared to the consensus estimate of $81.61 million. Luminex had a negative net margin of 0.80% and a negative return on equity of 0.78%. The firm's revenue was up 4.4% on a year-over-year basis. During the same period last year, the business posted $0.15 EPS. View Luminex's Earnings History.

Luminex is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Luminex.

Luminex updated its third quarter 2019 earnings guidance on Wednesday, July, 31st. The company provided EPS guidance of for the period. The company issued revenue guidance of $80-83 million, compared to the consensus revenue estimate of $83.01 million.

2 brokerages have issued 12 month target prices for Luminex's stock. Their predictions range from $33.00 to $33.00. On average, they anticipate Luminex's share price to reach $33.00 in the next twelve months. This suggests a possible upside of 47.7% from the stock's current price. View Analyst Price Targets for Luminex.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Luminex.

Media coverage about LMNX stock has been trending negative on Tuesday, according to InfoTrie. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Luminex earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave press coverage about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Luminex.

Some companies that are related to Luminex include Cantel Medical (CMD), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI), Nevro (NVRO), Glaukos (GKOS), Irhythm Technologies (IRTC), Cardiovascular Systems (CSII), Merit Medical Systems (MMSI), Atrion (ATRI), Cryolife (CRY), Silk Road Medical (SILK), Tactile Systems Technology (TCMD), AtriCure (ATRC) and Orthofix Medical (OFIX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include Baidu (BIDU), Mondi (MNDI), Alphabet (GOOG), Intel (INTC), Micron Technology (MU), Nektar Therapeutics (NKTR), Verizon Communications (VZ), Ligand Pharmaceuticals (LGND), NanoString Technologies (NSTG) and Rocket Pharmaceuticals (RCKT).

Luminex's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.06%), Vanguard Group Inc. (9.98%), RGM Capital LLC (6.79%), Renaissance Technologies LLC (5.09%), Northern Trust Corp (2.15%) and Investment Management of Virginia LLC (2.12%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Nachum Shamir and Todd C Bennett. View Institutional Ownership Trends for Luminex.

LMNX stock was sold by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Citadel Advisors LLC, JPMorgan Chase & Co., Invesco Ltd., Bank of America Corp DE, GSA Capital Partners LLP, Renaissance Technologies LLC and Panagora Asset Management Inc.. View Insider Buying and Selling for Luminex.

LMNX stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, RGM Capital LLC, BlackRock Inc., Crawford Investment Counsel Inc., Marshall Wace LLP, D. E. Shaw & Co. Inc., Investment Management of Virginia LLC and Vanguard Group Inc.. View Insider Buying and Selling for Luminex.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LMNX stock can currently be purchased for approximately $22.34.

Luminex has a market capitalization of $1.01 billion and generates $315.82 million in revenue each year. The medical instruments supplier earns $18.51 million in net income (profit) each year or $0.48 on an earnings per share basis. Luminex employs 988 workers across the globe.View Additional Information About Luminex.

The official website for Luminex is http://www.luminexcorp.com/.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]